lipid nanoparticles

	NCT Number	Title	Authors	Description	Identifier	Dates
1	pubmed:36054945	A rapid and quantitative reversed-phase HPLC-DAD/ELSD method for lipids involved in nanoparticle formulations	Yannick Mousli Mathilde Brachet Jeanne Leblond Chain Ludivine Ferey	Lipid nanoparticles (LNPs) have shown great success as drug delivery systems, especially for mRNA vaccines, as those developed during the Covid-19 pandemics. Lipid analysis is critical to monitor the formulation process and control the quality of LNPs. The present study is focused on the development and validation of a high-performance liquid chromatography - diode array detector - evaporative light scattering detector (HPLC-DAD/ELSD) based method for the simultaneous quantification of 7 lipids,	pmid:36054945 doi:10.1016/j.jpba.2022.115011	Fri, 02 Sep 2022 06:00:00 -0400
	pubmed:36056015	SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®, induces robust humoral and cellular immunity in mice and non- human primates	Reza Alimohammadi Meysam Porgoo Mohamad Eftekhary Seyed Hossein Kiaie Ehsan Ansari Dezfouli Maryam Dehghani Kaveh Nasrollahi Talieh Malekshahabi Maryam Heidari Sedigheh Pouya Masoumeh Alimohammadi Dorsa Sattari Khavas Mohammad Sadra Modaresi Mohammad Hossein Ghasemi Hamed Ramyar Fatemeh Mohammadipour Fateme Hamzelouei Ahmadreza Mofayezi Seyed Saeed Mottaghi Amirhosein Rahmati Mohsen Razzaznian Vista Tirandazi Mahdi Tat Fatemeh Borzouee Hossein Sadeghi Melika Haji Mohammadi Leila Rastegar Seyed Milad Safar Sajadi Hossein Ehsanbakhsh Hamed Bazmbar Zeinab Baghernejadan Maedeh Shams Nouraei Pouya Pazooki Mina Pahlavanneshan Khadijeh Alishah Fateme Nasiri Neda Mokhberian Seyedeh Shima Mohammadi Shima Akar Hamidreza Niknam Marzieh Azizi Mohammad Ajoudanian Mohammad Hossein Moteallehi-Ardakani Seyed Ali Mousavi Shaegh Reihaneh Ramezani Vahid Salimi Reza Moazzami Seyed Mahmoud Hashemi Somaye Dehghanizadeh Vahid Khoddami	At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology offers a flexible and scalable platform to address the urgent need for worldwide immunization in pandemic situations. This strategic powerful platform has recently been used to immunize millions of people proving both of safety and highest level of clinical efficacy against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we provide preclinical report of COReNAPCIN^(®); a vaccine	pmid:36056015 doi:10.1038/s41541-022-00528-3	Fri, 02 Sep 2022 06:00:00 -0400